Nux vomica 30C,
does it really help with Relief of heartburn and dyspepsia?
research showsNux vomica 30C is rated F with 8 points for heartburn and dyspepsia. A 30C preparation repeats a 100-fold dilution thirty times, reaching about 10^-60, so even a one-mole starting solution has no realistic chance of leaving a source-material molecule in a usual dose. Old placebo-controlled Nux vomica D4 and D30 gastropathy trials were small or low quality and did not show significant symptom improvement over placebo. Meta-analysis of larger higher-quality homeopathy trials was also compatible with no specific effect, while a positive 2026 individualized-homeopathy dyspepsia trial used multiple remedies and cannot be attributed to single-ingredient Nux vomica 30C.
ads claimMarketing matches broad stories about toxins, overeating, and stress to a personalized remedy effect. Direct pharmacology of a 30C pill cannot be explained by source-material dose, and natural fluctuation, diet changes, consultation, and expectancy must be separated from a product-specific effect.
Useful facts when choosing a product
- Nux vomica denotes a strychnine-containing source plant, but 30C is a homeopathic label indicating thirty successive 100-fold dilutions of the starting material.
- An ideal 30C preparation is about 10^-60, leaving no realistic chance of a source-material molecule in a usual dose; it is chemically and toxicologically different from a low-dilution or herbal Nux vomica extract.
- Sugar pellets or dilute liquid excipients make up most of the product, so actual labeled sugars, alcohol, allergens, and manufacturing quality should be checked product by product.
- Difficulty swallowing, bleeding, anemia, repeated vomiting, weight loss, chest pain, or persistent heartburn should not be delayed by homeopathic self-treatment and requires evaluation.
What the research actually shows
The trial-characteristics table used by Shang and colleagues lists Nux vomica gastropathy trials with 16 participants at D30, 53 at D4, and 147 at D4, none classified as high quality. Summaries of these old studies report no statistically significant symptom difference from placebo. Shang and colleagues compared 110 placebo-controlled homeopathy trials with 110 conventional-medicine trials and found the larger higher-quality homeopathy trials compatible with placebo. Mathie and colleagues' 2017 meta-analysis of nonindividualized homeopathy reported selected overall signals but low-quality evidence, sparse condition-specific trials, and no confirmation of Nux vomica 30C for heartburn.
Why this is classified as F (8)
Null placebo comparisons in direct gastropathy trials, the approximately 10^-60 dilution and absence of active source material, and repeated refutation in larger higher-quality homeopathy evidence yield F with 8 points, consistent with other 30C corpus verdicts. Direct toxicity and treatment-delay risk remain separate safety questions.
Counterpoint. Improvement can reflect food, alcohol, or caffeine changes, natural symptom fluctuation, and placebo or consultation effects. Recurrent heartburn is better addressed by evidence-based lifestyle measures, assessment of antacid or acid-suppression options, and evaluation for Helicobacter pylori or other causes.
Rejudgment record. New verdict — Assigned F based on null placebo comparisons in Nux vomica D4 and D30 gastropathy trials, effectively absent source material at the approximately 10^-60 30C dilution, placebo-compatible findings in larger higher-quality homeopathy trials, and corpus consistency with Glonoinum 30C
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Relief of heartburn and dyspepsia | F | Direct placebo-controlled gastropathy trials found no significant difference, and 30C contains no pharmacological amount of source material. |
| Effective absence of source-material molecules at 30C | A | Thirty successive 1:100 dilutions produce 10^-60, far beyond the Avogadro limit. |
| A specific homeopathy effect beyond placebo | F | Larger higher-quality trials and public or academic syntheses do not support a robust reproducible specific effect. |
Cross-check — Codex and Claude
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Nux vomica gastropathy trials summarized in Shang et al. 2005 | Set of older double-blind placebo-controlled trials | 16 | Unclear in old reports | Global assessment of gastropathy symptoms | Did not show statistically significant symptom improvement over placebo and were not classified as high-quality trials. | Direct null Nux vomica evidence of low methodological quality |
| Shang A et al. 2005 | Comparative meta-analysis of placebo-controlled homeopathy and conventional-medicine trials | 110 | Swiss federal evaluation program | Specific treatment effects accounting for trial size and quality | Larger higher-quality homeopathy trials were compatible with placebo effects rather than a specific effect. | Class-level refutation |
| Mathie RT et al. 2017 | Systematic review and meta-analysis of nonindividualized homeopathy randomized trials | 75 | Homeopathy Research Institute and related support | Main effect versus placebo across conditions | Despite selected overall signals, evidence quality was low and condition-specific data sparse, providing no confirmation for Nux vomica 30C heartburn. | Class-level uncertainty including a homeopathy-favorable perspective |
Receipt — 3 References
All 3 cited sources were verified for existence at the original page (as of 2026-07-20).
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-20 · Corrections: none
Cite this verdict
[Chamgap] Nux vomica 30C x relief of heartburn and dyspepsia — Evidence Grade F·8. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/general/nux-vomica-30c-heartburn-dyspepsia-homeopathy/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.